Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Cash from Financing Activities (2020 - 2025)

Biofrontera has reported Cash from Financing Activities over the past 6 years, most recently at $2.4 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $2.4 million for Q4 2025, down 41.98% from a year ago — trailing twelve months through Dec 2025 was $6.1 million (down 58.87% YoY), and the annual figure for FY2025 was $10.8 million, down 26.86%.
  • Cash from Financing Activities for Q4 2025 was $2.4 million at Biofrontera, down from $4.0 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for BFRIW hit a ceiling of $43.8 million in Q4 2021 and a floor of -$298000.0 in Q3 2024.
  • Median Cash from Financing Activities over the past 5 years was $4.3 million (2022), compared with a mean of $7.3 million.
  • Biggest five-year swings in Cash from Financing Activities: soared 3926.45% in 2022 and later crashed 150.42% in 2024.
  • Biofrontera's Cash from Financing Activities stood at $43.8 million in 2021, then tumbled by 89.44% to $4.6 million in 2022, then soared by 45.01% to $6.7 million in 2023, then crashed by 39.68% to $4.0 million in 2024, then crashed by 41.98% to $2.4 million in 2025.
  • The last three reported values for Cash from Financing Activities were $2.4 million (Q4 2025), $4.0 million (Q4 2024), and -$298000.0 (Q3 2024) per Business Quant data.